文献速递主动脉疾病

烟囱技术与开窗技术腔内修复近肾腹主动脉瘤的单中心对比评估

Monocentric Evaluation of Chimney Versus Fenestrated Endovascular Aortic Repair for Juxtarenal Abdominal Aortic Aneurysm.
PubMed 文献 · Ann Vasc Surg · 2017-02-02

住院死亡率烟囱组显著更高(16.1% vs 3.3%),但中期生存、再干预及靶血管通畅率无显著差异,开窗组I型内漏免除率更优。

要点

  • 烟囱EVAR住院死亡率显著高于开窗EVAR(16.1% vs 3.3%,P=0.03)。
  • 开窗EVAR的I型内漏免除率在12和24个月均显著更优(P=0.01)。
  • 两组中期生存、再干预及靶血管通畅率无显著差异。

核心结论

  • 烟囱EVAR在本系列中显示出有希望且持久的中期结果,与开窗EVAR相比不应视为对立策略而应互补。

研究设计与样本

  • 单中心回顾性分析2010年1月至2015年1月前瞻性收集的数据,纳入因合并症过多不适合开放手术的近肾腹主动脉瘤患者。

主要发现

  • 烟囱组平均年龄显著更高(开窗组71.3±8.2岁 vs 烟囱组75.3±6.6岁;P=0.02),术前慢性肾病比例显著更高(13例[14.4%] vs 12例[38.7%];P=0.009)。
  • 靶血管成功重建率开窗组99.0%(196/198) vs 烟囱组97.4%(38/39)(P=0.3)。
  • 住院死亡率烟囱组显著更高(3.3% vs 16.1%;P=0.03),急性肾损伤和慢性肾病发生率两组无显著差异。
  • 12和24个月总生存率开窗组91.4% vs 烟囱组82.1%和81.8% vs 69.0%(P=0.4),免于动脉瘤相关再干预率93.3% vs 82.1%和84.9% vs 82.1%(P=0.6),靶血管一期通畅率97.5% vs 89.9%(P=0.06)。
  • 开窗EVAR在12和24个月免于I型内漏生存率显著更高(100% vs 89.0%和97.7% vs 89.0%;P=0.01),动脉瘤最大横径缩小两组无显著差异。

临床怎么用

  • 烟囱EVAR具有现货可用、通用性强和低Profile器件的潜在优势,可作为开窗EVAR的互补选择。
  • 选择烟囱EVAR时需权衡其较高的住院死亡率,并加强围手术期管理。
  • 开窗EVAR在减少I型内漏方面表现更优,长期随访中需关注内漏监测。

局限性

  • 单中心回顾性研究,样本量有限(烟囱组仅31例),两组基线特征存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With approval of on-label fenestrated (F-) endovascular aortic repair (EVAR), concerns regarding long-term patency and endoleaks (ELs) after chimney graft (CG)-EVAR were raised. To add supportive data on the value of this technique, we chose to report the midterm results of CG-EVAR in a single center with standardized methods and to compare them to F-EVAR. METHODS: A retrospective analysis of prospectively gathered data from January 2010 to January 2015 was conducted, and patients with excessive comorbidities for open repair treated by CG-EVAR or F-EVAR were included. RESULTS: Ninety patients were treated by F-EVAR (88 men, 198 targets vessels) and 31 by CG-EVAR (26 men, 39 targets vessels, 12.9% treated in emergency; P = 0.001). Mean age was significantly higher in the CG group (71.3 ± 8.2 years in the FG group vs. 75.3 ± 6.6; P = 0.02), and there were significantly more patients suffering from preoperative chronic kidney disease (CKD) (13 [14.4%] treated by F-EVAR vs. 12 [38.7%]; P = 0.009). Target vessels were successfully reconstructed in 99.0% (196/198 target vessels) vs. 97.4% (38/39 target vessels) of cases (P = 0.3). In-hospital mortality was significantly higher after CG-EVAR (3.3% vs. 16.1%; P = 0.03). Incidence of acute kidney injury and CKD did not differ significantly between both groups. At 12 and 24 months, overall survival was 91.4% after F-EVAR vs. 82.1% and 81.8% vs. 69.0% (P = 0.4), estimated freedom from aneurysm related reintervention was 93.3% vs. 82.1% and 84.9% vs. 82.1% (P = 0.6), and target vessel's primary patency rate was 97.5% vs. 89.9% (P = 0.06), respectively. Freedom from type I EL's survival was significantly higher after F-EVAR at 12 and 24 months (100% vs. 89.0% and 97.7% vs. 89.0%; P = 0.01), but aneurysm maximum transverse diameter decrease did not differ significantly. CONCLUSIONS: There are potential advantages to CG-EVAR with off-the-shelf availability, versatility, and low-profile devices. In this series, patients treated by CG-EVAR showed promising and durable midterm results compared with F-EVAR. CG-EVAR and F-EVAR should not be apprehended as opposed strategies but more as complementary ones, while the best indications for CG-EVAR are clarified.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caradu C, Morin J, Poirier M, et al. Monocentric Evaluation of Chimney Versus Fenestrated Endovascular Aortic Repair for Juxtarenal Abdominal Aortic Aneurysm. Ann Vasc Surg. 2017. PMID: 28161566. doi:10.1016/j.avsg.2016.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。